key: cord-0853143-fpfojosz authors: Gupta, Pratibha title: A Review: Epidemiology, pathogenesis and prospect in developing vaccines for Novel Coronavirus (COVID-19) date: 2020-09-28 journal: Indian J Tuberc DOI: 10.1016/j.ijtb.2020.09.021 sha: 7e536237706138566fae7c3bffa676c6ce03ec3d doc_id: 853143 cord_uid: fpfojosz In December 2019, a large number of coronavirus cases were emerged in Wuhan, Hubei Province, China and rapidly spread to different countries and territories around the world within four months. The World Health Organization (WHO) declared this outbreak as a global health emergency. The spread of COVID-19 over globe is highly contagious; they transmitted from person-to-person through small droplets of infected person. Many diagnosis and treatment methods have been implemented to reduce and control the outbreak. Efforts have been made to develop coronavirus vaccine against S protein or spike glycoprotein of coronavirus. COVID-19 outbreak will affect the Gross Domestic Product (GDP) of the world. At the time of preparing manuscript, total number of active cases reaches to more than 8.9 million and confirmed death reaches to approx. 4.6 lakh. This article highlights the ongoing research and advances in designing vaccine and therapeutics against COVID-19 and also focusing on the epidemiology, transmission, future direction and control the spread of infectious diseases. Coronavirus is one of the most infectious pathogens that targets human respiratory system. In patients have no symptoms but they act as a carrier for the diseases. About 80% of infected people recover without any special treatment and approximately 1.0 out of 6.0 patients is seriously ill and facing breathing difficulty [5] . People having weak immunity, diabetes, heart problem, and are infected with coronavirus, need extra attention and clinical care [6] . COVID-19 spread from person to person through small droplets, when infected person cough, exhale or speaks. This is why it is important to keep distance of at least 3 to 6 feet from a person who is ill [5] . On 11th March 2020, WHO declared COVID-19 as a pandemic disease [7] . All the country are doing their best and implementing the appropriate control and preventive strategies. In the absence of specific medicines for treatment of COVID-19, drugs that might be effective include remdesivir, ritonavir, chloroquine (CQ) and hydroxychloroquine (HCQ) alone or in combination with covalescent plasma, monoclonal antibodies and Interferons [8, 9, 10, 11, 12] . Many efforts have been made to develop vaccine against CoV infection but there are certain limiting factors such as degree of cross-protection and their sequence diversity which prevent the development of suitable and effective vaccine J o u r n a l P r e -p r o o f [13] . According to WHO guideline, the infected patients must be provide with proper oxygen therapy, fluid therapy, medicine and also recommends proper isolation system. Coronavirus are enveloped virus, with single stranded, non-segmented, positive sense RNA belongs to the family Coronaviridae, subfamily Coronavirinae and order Nidovirales. Genome size of coronavirus is approximately 26-32 Kb and is the largest known genome of RNA virus [14] . Its size ranges from 60 nm to 140 nm in diameter having club-shaped spike projections (Fig 1) . Under electron microscope, spike looks like crown and hence named coronavirus [15] . Coronavirus have helically symmetrically nucleocapsids, which is very rare among positive sense RNA virus. On the basis of phylogeny, subfamily Coronavirinae consist of four genera: Alphacoronavirus (α-CoV), Betacoronavirus (β-CoV), Gammacoronavirus (γ-CoV) and Deltacoronavirus (δ-CoV). α -CoV and β -CoV usually causes respiratory problems in human, whereas γ -CoV and δ -CoV infect birds. In human two highly pathogenic viruses SARS-CoV and MERS-CoV, causes severe respiratory syndrome, whereas four human coronavirus HCoV-NL63, HCoV-OC43, HCoV-229E and HKU1 induced mild respiratory syndrome in immunocompetent person. According to current sequence database HCoV-OC43, HKU1 have originated from rodent and HCoV-NL63, HCoV-229E, SARS-CoV and MERS-CoV have originated from bats [14, 16] . Through sequencing, it was found that nCoV-2019 belongs to β -coronavirus [17] . China. This outbreak in China is the third epidemic in 21 st century, which already surpassed SARS and MERS. Currently, large number of pneumonia patients were reported, who had exposed to seafood market, which is a hub for many species of live animal. In January 10, 2020, full genome sequences of COVID-19 were released in public database, and were found that sequence has some similarity with SARS. 2019-nCoV was renamed as SARS-CoV-2 by International Committee on Taxonomy of Viruses. Genetic sequence of COVID-19 shows more than 80% similarity with SARS-CoV and 50% sequence identity with MERS-CoV [21] . Extensive study from the phylogenetic analysis revealed that the COVID-19 belongs to betacoronavirus genus. Binding of receptor is the first step of viral infection followed by fusion with the cell. It is reported that COVID-19 binds to angiotensin-converting enzyme 2 (ACE2), as the sequence of receptor binding domain of coronavirus spikes is similar to that of SARS-CoV [22] . in third trimester of pregnancy and confirmed for COVID-19 infection, but the transmission from mother to child was not confirmed. Pregnant women are more susceptible to infection by respiratory pathogens [24] . The S-protein based strategies such as S1 receptor binding domain (S1-RBD), DNA, viral vector, full length S protein etc. have been used for developing vaccine against COVID-19 [39, 40, 41] . S1-RBD interact with angiotensin-converting enzyme 2 (ACE2) and S2 domain of S protein mediate fusion of virus and host cell membrane for releasing viral RNA into the cytoplasm. The S protein plays a major role for induction of immunity during COVID-19 infection, which elicits antibodies and T-cell response [38] . Hence the S-protein based vaccine blocks not only viral binding receptor but also prevent viral genome uncoating [42] . Therefore full length or may be the appropriate part of S protein are most promising (Table 2) . Plasma from the patients recovered from COVID-19 has been potent and last resort to increase the survival rate of COVID-19 patients [45] . Several studies shows shorter hospital stay and decreased mortality in patients who are treated with plasma than those who are not treated with plasma. This technology was also previously used in case of MERS, 2009 pandemic influenza A H1N1 or in 2014 against Ebola virus disease [46, 47] . Recently it has been suggested by Food and Drug Administration that administration of CPT may provide an effective treatment against COVID-19 during public health emergency [48] . According to WHO, COVID-19 management is primarily focus on preventing infection transmission, early detection and proper health care support system. There are some limitation such as along with CPT patients receive antiviral drug, thus there is a possibility that these antiviral drugs may also contribute in the recovery of patients. Some patients also administered with glucocorticoids, which might interfere with immune response. • Individual with respiratory symptoms, advised to meet medical health care for proper treatment. • Regular hand wash with disinfection or soap and use of alcohol (at least 70%) based sanitizer. • Use of face mask, and avoid direct contact with infected person. • Safe distance of at least 1 meter should be maintained. • Health care are recommended to use N95 mask and FFPE kit while handling suspected or confirmed cases of coronavirus. • Avoid touching nose, eye and mouth without proper hand sanitization. • Patients with pre-existing medical condition such as diabetes, asthma, heart disease etc. may continuously be in contact with their medical supervisor. Global economy will suffer the worst financial crisis, said the International Monetary Fund as the planet is struggling with the COVID-19 pandemic. IMF has estimated that in 2020 the growth for global GDP is estimated to fall to -3 % (Fig. 3) and will rebound to 5.8 % in 2021. The cumulative global loss due to COVID-19 in year 2020 and 2021 is expected to be around Person-to-person contact was minimized to control the spread of COVID-19 infection. Tables Table 1: Diagnostic test kits used for the diagnosis of COVID-19 Table 2 : Clinical-phase vaccine for COVID-19 Section: Frequently Asked Questions (FAQs) on coronaviruses Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020 WHO Director-General's opening remarks at the media briefing on COVID-19 -11 M arch 2020 Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV Drug treatment options for the 2019-new coronavirus Potential antiviral therapeutics for 2019 novel coronavirus A decade after SARS: strategies for controlling emerging coronaviruses Epidemiology, genetic recombination, and pathogenesis of coronaviruses Virology: Coronavirus Molecular evolution of human coronavirus genomes Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Clinical features of patients infected with 2019 novel corona virus in Wuhan Identification of a novel coronavirus causing severe pneumonia in human: A descriptive study Clinical considerations for patients with diabetes in times of COVID-19 epidemic Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Novel Wuhan (2019-nCoV) coronavirus The spike protein of SARS-CoV-a target for vaccine and therapeutic development A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice SARS vaccine development Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human The COVID-19 vaccine development landscape Convalescent plasma transfusion for the treatment of COVID-19: Systematic review Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol Food and Drug Administration. Recommendation for Investigational COVID-19 Convalescent Plasma Primerdesign Ltd COVID-19 genesig Real-Time PCR assay Primerdesign Ltd Abbott Realtime SARS-CoV-2 PerkinElmer® SARS-CoV-2 Real-time RT-PCR Real-time fluorescent RT-PCR kit for detecting 2019-nCoV BGI Europe A/S Detection Kit for Of Sun Yat-sen University RealStar SARS-CoV-2 RT-PCR kit 1.0 Altona Diagnostics